Market Research Logo

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2016’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
  • The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects
  • The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Peripheral Neuropathy (Sensory Neuropathy) Overview
Therapeutics Development
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies
Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes
Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development
Araim Pharmaceuticals, Inc.
CSL Limited
GeNeuro SA
Mitsubishi Tanabe Pharma Corporation
Neuren Pharmaceuticals Limited
Pfizer Inc.
Pharnext SAS
Polyneuron Pharmaceuticals AG
RegeneRx Biopharmaceuticals, Inc.
Sanofi
Shire Plc
Teijin Pharma Limited
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(baclofen + naltrexone + sorbitol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(hyaluronidase (human) (recombinant) + immune globulin (human)) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aminoquinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cibinetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDE-1204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fingolimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GL-2045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNbAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNZ-2591 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGN-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-184841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products
Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones
Featured News & Press Releases
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent
Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy
Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen
Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by CSL Limited, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pharnext SAS, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Sanofi, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Shire Plc, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H2 2016
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2016
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report